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Ned, 33, is single and currently living on social assistance in a
men’s shelter in the downtown core. He has been using prescription
opioids (“pain killers”) recreationally about four or five days a
week for the past 10 years. Typically, Ned uses prescription drugs
such as Percocet, Percodan, MS Contin, and OxyContin,
although he also uses Tylenol 3 and methadone depending on
what’s available on the street and what he can afford. Ned
makes a living from small-scale drug dealing, panhandling and
occasional thefts. Some of the medication Ned uses was prescribed
for his back pain and comes from a doctor in a walk-in clinic.
He supplements this supply with drugs from a street dealer who
gets them by “doctor shopping”—faking symptoms of chronic
pain to obtain multiple prescriptions for pain medication from
a number of doctors and various local pharmacies.
Abuse of controlled prescription drugs in Canada
In Canada, as in many other parts of the world, the problem of prescription drug abuse
is not new. Twenty-five years ago, an editorial in the Canadian Medical Association Journal 1
pointed out the problem of abuse of narcotic pharmaceuticals and highlighted the need
for more knowledge and better control. From an examination of current statistics, it
appears the words of the editorialists are more relevant today than they were in 1979.
The Compendium of Pharmaceuticals and Specialties (CPS), published by the Canadian
Pharmacists Association, lists hundreds of licit drugs, medications, and pharmaceutical
preparations.2 This chapter will restrict its focus to the non-medical or recreational use of
drugs with psychotropic properties; that is, substances governed by the United Nations
international conventions on narcotics and psychotropic substances. These include opi-
ate-based drugs for pain relief, tranquillizers such as benzodiazepines, stimulants and
amphetamines, and sedatives and barbiturates. In Canada, such “controlled” substances
are subject to the Controlled Drugs and Substances Act (CDSA), which divides them into
various categories or schedules.3
Extent of prescription drug abuse in Canada
There are no accurate statistics on the number of people in Canada who engage in the
non-medical use of prescription drugs or who experience dependence on prescription
drugs. Currently, there are no national monitoring systems or comprehensive surveillance
mechanisms in place to record and track the extent of non-medical use of prescription
drugs. As a result, the extent and nature of prescription drug abuse can only be measured
indirectly by analyzing distribution and sales statistics, and year-to-year trends in prescription
practices for specific classes of drugs.
These sources tell us that Canadians are among the heaviest consumers of psychotropic
medications in the world. For example, in 2002, Canada reported the fourth highest per
capita use of prescription narcotics in the world, the second highest use of sedative-hypnotics
(including benzodiazepines), and was among the top 15 countries in the use of prescription
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amphetamines.4,5 These high per capita consumption rates have
been reflected in various surveys, but no domestic survey has
attempted to determine or estimate the extent of non-medical use
or abuse of prescription drugs. National consumption rates of
psychotropic medications are relatively poor indicators of abuse.
Other indirect indicators of prescription drug drug abuse include
reported thefts and fraud (forgery and fraudulent alteration of pre-
scriptions) from pharmacies, hospitals, clinics, and doctors’ offices. 
The extent and nature of prescription drug abuse can also be esti-
mated by examining admissions data from detoxification centres,
treatment programs and emergency departments, by reviewing
coroners’ reports on overdose deaths, and by analyzing the type and
severity of substance abuse problems within the prison population.6
Toronto’s Centre for Addiction and Mental Health (CAMH)
studied admissions to treatment in Ontario in 1999-2000 and
found that as many as 11% of individuals reported prescription
drugs as part of their substance abuse problem.7
Some countries have mounted national surveys and monitoring
systems—including the National Household Survey on Drug
Abuse,8 and the Drug Abuse Warning Network (DAWN)9 in the
United States, and the National Drug Household Survey10 in
Australia—that directly measure prescription drug abuse. For
example, the 2001 U.S. National Household Survey on Drug
Abuse revealed that more than 11 million people (8% of the U.S.
population over the age of 12) had engaged in the non-medical use
of drugs. The results of these surveys also indicate that non-medical
use has been increasing over the past 10 years for all major groups
of prescription drugs.11,12
In Atlantic Canada, a task force examined the abuse of the semi-
synthetic opioid analgesic, OxyContin, and found that a small
number of physicians were responsible for writing prescriptions for
large quantities of OxyContin and other controlled substances
such as benzodiazepines.13 For example, data generated in
Newfoundland and Labrador by the province’s pilot prescription
monitoring program revealed that while 68% of physicians wrote
fewer than 100 prescriptions during a 16-month period, 2% wrote
more than 2,500 prescriptions, and 1% wrote more than 5,000
prescriptions for controlled substances.14
How does diversion of prescription drugs occur?
The diversion of prescription drugs away from their intended use
occurs in a variety of ways. The following list summarizes some of
the more common ways by which prescription drugs may become
available for non-medical use.15,16,17
• “Doctor shopping” or “double doctoring”—obtaining multiple
prescriptions from different doctors
• Theft from doctors’ offices, pharmacies and wholesalers, clinics,
and hospitals
• Prescription pad theft and tampering resulting in forged or
altered prescriptions
• Physician fraud—fraudulent prescriptions written by doctors in
return for money
• Purchases from friends, relatives, or dealers for whom the drug
has been legitimately prescribed
• Theft during break-and-entry robbery of private premises; robbery
of individuals leaving a pharmacy
• Diversion at the wholesale or retail level (including theft during
transportation and distribution)
• Diversion of drugs from substance abuse treatment programs
(for example, methadone)
• Purchase of drugs on the Internet 
Who abuses prescription drugs?
Overall, research indicates that prescription drug abuse occurs in
many segments of society, and adolescents and young adults,
older adults, women and the Aboriginal population seem to be
particularly at risk. For example, the U.S. National Household
Survey on Drug Abuse found the highest rates of non-medical use
of prescription drugs among adolescents and young adults.
Younger prescription drug abusers often use multiple substances,
both legal and illegal.18
The OxyContin task force in Atlantic Canada found that a growing
number of young people were abusing OxyContin. In a six-month
period, about 50 of these young people were admitted to an
outpatient mental health counselling service in St. John’s, NL.19
Non-medical use of prescription drugs seems to start in adolescence
and may evolve into abuse of multiple substances during adulthood.
There are indications that the risk for overdose deaths is higher if
prescription drug abuse is involved.20
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Despite big mark-ups on the street, it may still be cheaper
and easier for individuals with substance abuse problems to
get their hands on prescription drugs than to buy an illegal
drug such as heroin.
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Women were shown to be 50% more likely than men to abuse
prescription drugs in an analysis of U.S. data,21,22 while men were
more prone to engage in heavy alcohol use along with their non-
medical use of prescription drugs.23
Abuse of prescription drugs has long been a problem for Aboriginal
peoples in Canada24 and remains so today,25 although accurate
prevalence data are scarce.
Data suggest that as many as 20% of Canadian adults aged 60 or
older may be involved in long-term continuous use of pain relief
medications.26 A sizeable proportion of these engage in prescription
misuse, especially in the form of overuse and incorrect use of
medications. In general, the elderly tend to use psychotropic
prescription drugs more often than younger people and may
receive higher doses of benzodiazepines (tranquillizers) for longer
periods of time than is medically necessary. Long-term use has a
variety of negative consequences, including higher risks for
dependence, falls and other accidents, and impaired thinking. In
a Quebec study, it was found that among benzodiazepine users,
the elderly used the most prescriptions and were the least informed
about the effects and potential side effects.27
Why are prescription drugs diverted for 
non-medical purposes?
A number of factors explain the popularity of prescription drug
diversion. First, trafficking in prescription drugs can be highly
lucrative. A 1998 study in Vancouver confirmed that there are
huge mark-ups (and profit margins) in the street value of various
drugs. For example, a 60mg tablet of MS Contin (slow-release
morphine) cost $1.70 in a pharmacy, but on the street sold for an
average of $35 (a 2,059% mark-up). A 4mg Dilaudid tablet cost
$0.32 in the pharmacy and had an average street value of $32
(a 7,800% mark-up).28 In fact, trafficking in prescription drugs is
a rare case of contraband gaining value at the “retail” level. By
contrast, a stolen TV or VCR would rarely sell for more than its
retail price. And drugs are much easier to conceal and transport
than TVs and VCRs.
Despite big mark-ups on the street, it may still be cheaper and
easier for individuals with substance abuse problems to get their
hands on prescription drugs—either through double-doctoring or
paying the dealer mark-up—than it is to buy an illegal drug such as
heroin.29 Prescription drugs that wind up being used for non-medical
purposes are sometimes paid for by drug plans or social assistance. 
Prescription drug diversion may also be popular because non-
medical users believe that drugs produced legally by reputable
pharmaceutical companies are somehow better and safer than
drugs created illegally in dirty underground labs with questionable
ingredients by untrained individuals who may have direct links
with organized crime. While this may be true in principle, the
high rate of problematic use, dependence, and overdose from the
abuse of prescription drugs suggests that it is a serious societal
problem. Users may also believe they are less likely to be hassled
by police if they get caught with prescription drugs than they
would be with drugs such as heroin or crack.
Finally, the production, distribution and administration of prescrip-
tion drugs nationally employs literally tens of thousands of people.
There are also thousands of pharmacies, hospitals, clinics, and
doctors’ offices across the country. Despite the professionalism
and ethical conduct of the overwhelming majority of individuals
involved in this process, it only takes a handful of corrupt individ-
uals driven by greed to supply large geographical regions of the
country with prescription drugs for non-medical use.
What can be done to address prescription drug abuse? 
The typical response to this question has been to call for better
education and training—for the prescribing physician, the dispens-
ing pharmacist, and the patient. For example, physicians can be
taught to recognize patients’ drug-seeking behaviour and other
warning signs, to educate patients about their drug regimens, and
to set firm but reasonable prescribing guidelines.30 Other forms of
public education may focus on the effects of various substances. 
While the goals of education and training for both medical pro-
fessionals and patients have merit, research indicates that unless
these efforts are accompanied by formal notification to physicians
about their prescribing practices, they have little or no effect on
physician behaviour.31
Other possible preventive measures include better regulation of
prescribing and dispensing for physicians and pharmacists.
However, such regulations have only been shown to work if they
are enforced and there are consequences for misconduct.32
Regulations require monitoring by government and diversion
control programs similar to the electronic tracking systems in
place in several U.S. states33 and some Canadian provinces.
Electronic monitoring and tracking of prescriptions looks promising
as a way to reduce double-doctoring and the risk to patients of
problematic use. The PharmNet system in British Columbia was
singled out by the House of Commons Special Committee on
Non-Medical Use of Drugs as a comprehensive prescription tracking
and monitoring system that could serve as a model for the rest of
Canada. Further, the OxyContin task force in Atlantic Canada
recommended that Health Canada implement a formal reporting
system for all prescription narcotic drugs.34
To date, five Canadian provinces (British Columbia, Alberta,
Saskatchewan, Manitoba, and Nova Scotia) have implemented
multiple copy prescription tracking programs in an effort to reduce
the diversion of certain drugs that are at high risk for diversion
and abuse. Although these programs have not been extensively
researched, available studies suggest that the introduction of
multiple copy prescription programs results in some physicians
substituting drugs that fall outside the program,35 and may lead to
increased prescribing of less appropriate drugs.36
Finally, concerns about the abuse of certain medications could
prompt the medical community to consider alternative therapeutic
practices for pain management, and for other medical conditions
that are being routinely treated with drugs. However, this would
have to be done in a way that does not deprive patients of pain
medication if they need it. 
Conclusions and implications for Canada
Although exact figures are not yet available, the abuse of prescription
drugs constitutes a significant public health problem in Canada.
A recent report by the Auditor General of Canada calls for
improved analysis and dissemination of information on patterns
of drug use in Canada.37 Clearly, there is an illegal street market
for many prescription drugs in Canadian cities and there are real
monetary incentives for trafficking in these products.
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At a glance: solutions to 
prescription drug abuse
• In 2002, the House of Commons Special Committee on Non-
Medical Use of Drugs called for the development of real-time
databases to track prescribing and dispensing of commonly
misused prescription drugs.38 The PharmNet system in British
Columbia could provide a sophisticated model for monitoring
the use of prescription drugs.
• Cost-effective solutions to prescription drug abuse require a
comprehensive, permanent system that accurately captures
the nature, extent, and consequences of abuse. Occasional
surveys cannot accurately provide the kind of information we
need to address the abuse of pharmaceutical drugs in Canada.
• Economic incentives for the diversion and illegal sale of pre-
scription drugs are so overwhelming that a highly effective
regulation and enforcement system is required; otherwise,
virtually any response will be ineffective. 
• Even the smallest break in the production, distribution, and
administration chain has the potential to flood large geograph-
ical regions of the country with prescription drugs that can be
purchased for non-medical consumption.
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It also appears that some doctors are too quick to prescribe drugs
that have a potential to be abused. We learned that a small number
of doctors in Atlantic Canada, for example, write disproportionately
large numbers of prescriptions for pain relief medication and other
controlled substances. We also understand that even the smallest
break at any point in the production, distribution, and administra-
tion chain can flood entire regions of the country with prescription
drugs for non-medical use.
Prescription drug abuse in Canada is a complex issue that imposes
serious costs on society, yet at the moment we have no way to
measure how big the problem is. Future research needs to focus
on understanding the extent of the problem and its consequences
for the health, social and economic well-being of Canadians. This
research is also critical for developing evidence-based interventions
to reduce harm from prescription drug abuse.
Addressing prescription drug abuse should be a major focus of
future Canadian drug policy. However, policy development in this
area needs to carefully and directly target the abuse of prescription
drugs while ensuring that there is no threat to the supply and
availability of these important medications for the legitimate
treatment of pain and illness.
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